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OBJECTIVE — The purpose of this study was to analyze the interrelationship among
oxidation, myocardial infarction (MI), and type 2 diabetes in a population-based case-
control study of MI.
RESEARCH DESIGN AND METHODS — Participants were 1,709 individuals from
western New York: 257 women and men with incident MI and 1,452 healthy control subjects
(aged 35–70 years). Lipid peroxidation was measured by plasma levels of thiobarbituric acid
reactive substances (TBARS). History of type 2 diabetes was determined by self-reported history
of medical diagnosis.
RESULTS — In multivariate analyses, there was no signiﬁcant difference in TBARS levels
between case and control subjects in both sexes. In subgroup analyses by diabetes status,
diabetic subjects, regardless of MI status, exhibited signiﬁcantly higher TBARS values than
nondiabetic subjects. For diabetic women, TBARS values were 1.84 and 1.83 nmol/ml for
case and control subjects, respectively. Values for nondiabetic women were 1.29 and 1.31
nmol/ml, respectively. In diabetic men, values were 1.65 and 1.97 nmol/ml for case and
control subjects, respectively. Values for nondiabetic men were 1.36 and 1.36 nmol/ml,
respectively.
CONCLUSIONS — Whereas type 2 diabetes may be an important correlate of lipid peroxi-
dation, clinical coronary heart disease may not.
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O
xidation has been hypothesized to
be one of the plausible pathogenic
mechanisms underlying the associ-
ations between coronary heart disease
(CHD) and abnormalities in glucose and
insulin metabolism (1). Although several
studies have demonstrated the presence
of increased oxidative stress in either
CHD or type 2 diabetes individually, very
little is known about the interrelationship
among oxidation, clinical atherosclerosis,
and type 2 diabetes in the general popu-
lation.Thus,thecurrentanalysisattempts
toexaminethiscomplexinteractionusing
data from a population-based case-





ple, identiﬁed as the Western New York
Health Study, were collected between
1996 and 2001 (2–3). In all, 1,197
women and men aged 35–70 years and
discharged alive with a diagnosis of
acute incident MI (4) (ICD9 410) were
recruited from hospitals in Erie and
Niagara counties in New York State
(75% of all area hospitals). Control sub-
jects were randomly selected among
residentsofErieandNiagaracountiesin
the age range of 35–70 years. A total of
2,850 control subjects were inter-
viewed, representing 59.5% of those
identiﬁed, contacted, and for whom we
could determine eligibility. Biomarkers
of lipid peroxidation were available for
3,615 individuals (969 case and 2,646
control subjects) out of the total num-
ber of participants (n  4,047; 1,197
case and 2,850 control subjects). The
present study focuses on the 1,709 partic-
ipants who were not taking statins or vi-
tamins at the time of the interview (257
case and 1,452 control subjects). This se-
lection was done to avoid biochemical in-
ﬂuences of these drugs on the oxidative
status of participants.
All participants received a clinical ex-
aminationthatincludedmeasurementsof
resting blood pressure, height, weight,
and abdominal height. All participants
were queried about their personal medi-
cal history, including physician diagnosis
of hypertension, type 2 diabetes, and hy-
percholesterolemia, and about a number
of lifestyle habits, including dietary hab-
its, alcohol consumption, and smoking
history. The reference time frame for
questions regarding dietary and alcohol
consumption habits was 12–24 months
before the MI (for case subjects) or the
interview (for control subjects). Hyper-
tension, type 2 diabetes, hypercholes-
terolemia, and smoking status were
assessed at the time of the MI (for case
subjects) or the time of interview (for
control subjects).
Blood was obtained by highly stan-
dardized protocols, including uniform
time of morning collection, fasting status
ofparticipants,phaseofthemenstrualcy-
cle (for women), and activity before phle-
botomy. The blood tubes used were
immediately protected from light, kept at
4°C, processed, and stored at 80°C
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ricacidreactingsubstances(TBARS),trig-
lycerides, and glucose were measured
using methods previously described
(2,5). Several quality control measures
were implemented to maintain assay ac-
curacy (2,6).
WeconductedtwosetsofANOVA.In
the ﬁrst set, comparisons of adjusted
TBARSlevelswereperformedforeachsex
by case/control status. In the second set,
we divided the study sample by diabetes
status; TBARS levels were compared be-
tween diabetic and nondiabetic partici-
pants within each sex for both case and
control subjects.
RESULTS—Case subjects were signiﬁ-
cantly older and less educated than con-
trol subjects in both sexes (mean  SD
age 55.1  8.5 vs. 52.1  9.5 years in
women; 55.5  9.0 vs. 52.4  10.3 years
in men). Among women, anthropometric
measuresweresigniﬁcantlyhigherincase
than in control subjects (mean  SD BMI
31.2  5.2 vs. 28.5  6.8 kg/m
2); like-
wise, the prevalence of postmenopausal
(76.4 vs. 56.9%) and nonwhite partici-
pants (19.4 vs. 8.1%) was signiﬁcantly
higher in case than in control subjects.
Case subjects of both sexes were signif-
icantly more likely to be current smok-
ers, whereas there was a signiﬁcantly
larger prevalence of current drinkers in
controlsubjectsonlyamongfemalepar-
ticipants. In both sexes, the prevalence
of three major CHD risk factors (type 2
diabetes, hypertension, and hypercho-
lesterolemia) was signiﬁcantly higher in
case than in control subjects (diagnosis
of diabetes 31.9 vs. 6.3% in women;
18.4 vs. 6.9% in men).
Triglycerides and fasting glucose
were signiﬁcantly correlated with TBARS
levels in both women and men (correla-
tion coefﬁcients ranging from 0.21 for
triglycerides to 0.51 for glucose). No sig-
niﬁcant correlations were found between
TBARS and smoking, drinking, or dietary
variables.
Inbothsexes,afteradjustmentforpo-
tential confounders, there was no signiﬁ-
cant difference in TBARS levels between
case and control subjects (1.38 and 1.34
nmol/ml for case and control female sub-
jects, respectively, and 1.37 and 1.41
nmol/ml for case and control male sub-
jects, respectively).
However, in subgroup analyses by
diabetes status (Table 1), diabetic partici-




adds to the growing body of literature on
the strong association between lipid per-
oxidation and abnormalities in glucose
and insulin metabolism (2–3,7–8). Fur-
thermore, our ﬁndings suggest that the
observed associations of increased oxida-
tive stress in individuals with clinical
manifestations of atherosclerosis (such as
MI) may be dependent on underlying ab-
normalities in glucose metabolism.
TBARS are strongly associated with
glucose and triglyceride levels in the gen-
eralpopulation(2)andmaybeelevatedin
individuals with impaired glucose toler-
ance and in diabetic subjects with poor
metabolic control (3). The present study
corroborates and extends these previous
observations, indicating that, whereas
type 2 diabetes may be an important cor-
relate of lipid peroxidation, clinical CHD
may not.
Thelimitations of this study include
itsobservationalnatureandthefactthat
biomarkers of lipid peroxidation were
measured after the occurrence of the
clinical event. A further limitation is the
limited speciﬁcity of TBARS as a marker
oflipidperoxidation(9–10).Moreover,
we relied on a self-reported history of
medical diagnosis of type 2 diabetes,
and this may misrepresent the true
prevalence of the disease. Finally, the
participation rate is suboptimal and
may restrict the generalizability of the
ﬁndings.
In summary, our ﬁndings suggest
that the presence of lipid peroxidation
in individuals with clinical manifesta-
tions of atherosclerosis may be depen-
dent on underlying abnormalities in
glucose metabolism; however, it is not
possible to rule out that, in the diabetic
population, oxidative stress may have a
signiﬁcant role in the pathogenesis of
CHD.
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